Skip to main content Skip to footer

Algernon Pharmaceuticals Inc.

  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Pipeline
    • Overview
    • NP-120 (Ifenprodil)
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual General Meeting
    • Analysts
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGW0
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • IR Calendar
  • Email Alerts
Jun 13, 2022 7:00am EDT

Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

May 05, 2022 7:00am EDT

Algernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough

Apr 26, 2022 7:00am EDT

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

Feb 23, 2022 7:00am EST

Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

Feb 04, 2022 7:00am EST

Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Jan 28, 2022 6:00am EST

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis

Jan 24, 2022 7:00am EST

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

Jan 19, 2022 7:00am EST

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Jan 14, 2022 8:15am EST

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

Jan 04, 2022 9:15am EST

Algernon Pharmaceuticals Issues Compensation Options

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • …Page 19
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap